Overview

Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.

Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of two different doses of MCC-135, once daily (QD) or twice daily (BID), on the disease state and the quality of life in subjects with congestive heart failure.
Phase:
Phase 2
Details
Lead Sponsor:
Takeda